Financial Instruments Assets and Liabilities Measured on Recurring Basis (Detail) (USD $) In Millions, unless otherwise specified	Jun. 29, 2014		Dec. 31, 2013
Other selected financial assets
Held-to-maturity debt securities, carried at amortized cost(c), (e)	$ 9,001	[1],[2]	$ 9,139	[1],[2]
Private equity securities, carried at equity-method or at cost(e), (f)	2,171	[2],[3]	2,270	[2],[3]
Total	11,172		11,409
Total selected financial assets	50,560		49,246
Other selected financial liabilities(h)
Short-term borrowings, carried at historical proceeds, as adjusted(e)	5,561	[2],[4]	6,027	[2],[4]
Long-term debt, carried at historical proceeds, as adjusted(i), (j)	32,267	[4],[5],[6]	30,462	[4],[5],[6]
Total	37,828	[4]	36,489	[4]
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value on a recurring basis	39,388	[7]	37,837	[7]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	391	[7],[8]	630	[7],[8]
Fair Value, Measurements, Recurring [Member] | Trading securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value on a recurring basis	105	[7],[9]	126	[7],[9]
Fair Value, Measurements, Recurring [Member] | Interest rate swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in receivable positions(d):	555	[10],[7]	468	[10],[7]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	90	[7],[8]	301	[7],[8]
Fair Value, Measurements, Recurring [Member] | Foreign currency swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in receivable positions(d):	637	[10],[7]	871	[10],[7]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	182	[7],[8]	110	[7],[8]
Fair Value, Measurements, Recurring [Member] | Foreign currency forward-exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative financial instruments in receivable positions(d):	122	[10],[7]	172	[10],[7]
Selected financial liabilities measured at fair value on a recurring basis(a)
Derivative financial instruments in a liability position(g):	119	[7],[8]	219	[7],[8]
Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Available for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value on a recurring basis	36,189	[1],[7]	34,899	[1],[7]
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Available for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value on a recurring basis	1,474	[7]	945	[7]
Other Assets [Member] | Fair Value, Measurements, Recurring [Member] | Available-for-sale equity securities, excluding money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value on a recurring basis	$ 306	[1],[7]	$ 356	[1],[7]

[1] Gross unrealized gains and losses are not significant.

[2] The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of June 29, 2014 or December 31, 2013. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities at cost are based on Level 3 inputs.

[3] Our private equity securities represent investments in the life sciences sector.

[4] Some carrying amounts may include adjustments for discount or premium amortization or for the effect of hedging the interest rate fair value risk associated with certain financial liabilities by interest rate swaps.

[5] Includes foreign currency debt with fair values of $669 million as of June 29, 2014 and $651 million as of December 31, 2013, which are used as hedging instruments.

[6] The fair value of our long-term debt (not including the current portion of long-term debt) is $37.0 billion as of June 29, 2014 and $35.1 billion as of December 31, 2013. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the condensed consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.The following table provides the classification of these selected financial assets and liabilities in the condensed consolidated balance sheets:(MILLIONS OF DOLLARS) June 29, 2014 December 31, 2013Assets Cash and cash equivalents $1,430 $1,104Short-term investments 30,648 30,225Long-term investments 17,168 16,406Other current assets(a) 203 286Other noncurrent assets(b) 1,111 1,225 $50,560 $49,246Liabilities Short-term borrowings, including current portion of long-term debt $5,561 $6,027Other current liabilities(c) 215 303Long-term debt 32,267 30,462Other noncurrent liabilities(d) 176 327 $38,219 37,119

[7] We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1C. Basis of Presentation and Significant Accounting Policies: Fair Value. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.

[8] Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $90 million and foreign currency forward-exchange contracts with fair values of $57 million as of June 29, 2014; and foreign currency swaps with fair values of $76 million and foreign currency forward-exchange contracts with fair values of $77 million as of December 31, 2013.

[9] Trading securities are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.

[10] Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $14 million and foreign currency forward-exchange contracts with fair values of $61 million as of June 29, 2014; and interest rate swaps with fair values of $38 million, foreign currency swaps with fair values of $30 million and foreign currency forward-exchange contracts with fair values of $66 million as of December 31, 2013.